| Literature DB >> 31930965 |
David Yl Chan1, Daniela Moralli2, Lucy Wheatley2, Julia D Jankowska2, Zoia L Monaco3.
Abstract
Gene expression studies and gene therapy require efficient gene delivery into cells. Different technologies by viral and non-viral mechanisms have been used for gene delivery into cells. Small gene vectors transfer across the cell membrane with a relatively high efficiency, but not large genes or entire loci spanning several kilobases, which do not remain intact following introduction. Previously, we developed an efficient delivery system based on herpes virus simplex type 1 (HSV-1) amplicons to transfer large fragments of DNA incorporated in human artificial chromosome (HAC) vectors into the nucleus of human cells. The HSV-1 amplicon lacks the signals for cleavage and replication of its own genome, yet each amplicon has the capacity to incorporate up to 150 kb of exogenous DNA. In this study, we investigated whether the capacity of gene delivery could be increased by simultaneously introducing multiple HSV-1 modified amplicons carrying a gene expressing HAC vector into cells with the aim of generating a single artificial chromosome containing the desired genes. Following co-transduction of two HSV-1 HAC amplicons, artificial chromosomes were successfully generated containing the introduced genes, which were appropriately expressed in different human cell types.Entities:
Keywords: Gene therapy; HPRT gene expression; Herpes simplex Virus-1 (HSV-1) amplicons; Human artificial chromosome (HAC); Multigene delivery
Mesh:
Year: 2020 PMID: 31930965 PMCID: PMC7066578 DOI: 10.1016/j.yexcr.2020.111840
Source DB: PubMed Journal: Exp Cell Res ISSN: 0014-4827 Impact factor: 3.905
Fig. 1A: Schematic of the three vectors used in this study. The constructs are not drawn to size. B: Diagram of the co-transduction technique, with the possible outcomes of the input DNA.
Fig. 2A: 21 GFP+17 RFP in HT0180 24 h after dual transduction. The left panel shows an image acquired with a 4× objective, displaying both GFP and RFP, while the two bottom panels show either GFP or RFP only. The right panel shows the same field, acquired with a 20× objective. The white bar corresponds to 50 μM in both panels. B: 17 RFP and HPRT GFP in different human cell lines 24 h after co-transduction with 17 RFP and HPRT GFP amplicons at a multiplicity of infection of MOI 2. The top panels show both GFP and RFP, while the bottom panels show either GFP or RFP only. The white bar corresponds to 50 μM.
Co-transduction efficiency in HT1080 cells after 24 h.
| 21 GFP +17 RFP | 21 GFP +17 RFP | ||
|---|---|---|---|
| Without centrifugation | With Centrifugation | Without centrifugation | |
| 11% | 16% | 15% | |
| 4.0% | 16% | 13% | |
| 0.4% | 6.0% | 5.0% | |
Fig. 3A: Left column D3-3 FISH. The D3-3 metaphase spreads were hybridised with the 17α DNA (green signal) and 21/13α DNA (red signals) probes. The chromosomes were counterstained in DAPI, blue. The HAC (yellow arrow) was labelled by both probes, as visible in the inset. The endogenous chromosome 17 (green arrows) are labelled by 17α only, while the endogenous chromosome 21 and 13 (red arrows) are labelled by the 21/13 probe only. Right column: LWB5 FISH. The LWB5 metaphase spreads were hybridised with the 17α DNA (green signal) and the HPRT DNA (red signal) probes. The chromosomes were counterstained in DAPI, blue. The HAC (yellow arrow) was labelled by both probes, as visible in the inset. The endogenous chromosome 17 (green arrows) were labelled by 17α only, while the endogenous HPRT locus (red arrows) were labelled by the HPRT probe only. B: Clones expressing either GFP or RFP only, or both. Top panels, iPSc DF19.9. Bottom panels, hESc HUES-2. C: Western blot analysis of HPRT expression in the LWB5 clone, and lack of expression in the HT1080 HPRT−/- parental cell lines compared to HT10180 WT control. GAPDH was used as loading control.
Efficiency of co-transduction in different human cell lines after 24 h.
| 17 RFP | HPRT GFP | 17 RFP + HPRT GFP | |
|---|---|---|---|
| 7% | 11% | 3% | |
| 18% | 26% | 3% | |
| 5% | 10% | 1% | |
| 1% | 20% | 1% |